PAC-14028 in Healthy Male Volunteers
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Amorepacific Corporation.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Amorepacific Corporation
Collaborator:
Ministry of Knowledge Economy
Information provided by:
Amorepacific Corporation
ClinicalTrials.gov Identifier:
NCT01264224
First received: December 20, 2010
Last updated: December 28, 2010
Last verified: December 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Primary Objective:
- To evaluate safety and tolerability of single and multiple oral dosing of PAC-14028 in healthy male volunteers.
Secondary Objective:
- To evaluate pharmacokinetics and pharmacodynamics of single and multiple oral dosing of PAC-14028 in healthy male volunteers.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Subjects |
Drug: PAC-14028 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Masking: Double Blind (Subject, Caregiver, Investigator) |
| Official Title: | A Dose-block Randomized, Double-blind, Placebo-controlled Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of PAC-14028 After Oral Administration in Healthy Male Volunteers. |
Further study details as provided by Amorepacific Corporation:
Primary Outcome Measures:
- Safety/Tolerability [ Designated as safety issue: Yes ]AE incidence pattern, abnormal findings in vital sign, ECG test, and clinical lab tests
Secondary Outcome Measures:
- Pharmacokinetics/dynamics [ Designated as safety issue: No ]
- PK:Concentration of PAC-14028 in Blood and Urine; Cmax, AUC
- PD:Heat pain threshold/tolerance
| Estimated Enrollment: | 90 |
| Arms | Assigned Interventions |
|---|---|
| Experimental: PAC-14028 |
Drug: PAC-14028
tablets, oral administration, single/multiple dosing, dose escalation
|
Eligibility| Ages Eligible for Study: | 20 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy men aged 20 to 45 years at the time of screening
Whose weight is 50kg or more, but less than 90 kg, and whose body mass index(BMI) is 19.0 kg/m^2 or more but less than 27 kg/m^2
-BMI (kg/m^2) = weight(kg) /{height(m)}^2
- Who voluntarily decides study participation after receiving detailed explanation about the study and fully understanding it and who provides written consent for compliance with study requirement including proper contraception.
Exclusion Criteria:
- Who has clinically significant medical history or diseases involving liver, kidney, neurological system, respiratory system, endocrine system, urinary system, cardiovascular system, psychical disorders or blood tumor
- Who has gastrointestinal diseases or operation history which may interfere study drug absorption (however, except simple appendectomy and hernioplasty )
- Who has a history of hypersensitivity or allergies to any drug (aspirin, antibiotics, etc)
- Who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
- Who has drug abuse history or positive result at urine screening tests (cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine)
- Smoker or who has stopped smoking within previous 1 month or shows positive result at cotinine test.
- Who has confirmed positive at serological tests (HBs antigen, HCV antibody and HIV antibody)
- Who consistently consumes alcohol (over 21 units/week, 1 unit = 10 g of pure alcohol)
- Who has participated in other clinical study within 12 weeks before study drug administration (however, the last dosing day is considered as the end of clinical study.)
- Who has had bleeding or blood collection and donation over 400 mL within 12 weeks before study drug administration
Whose vital sign measured at sitting position after resting at least 5 minutes is as following
- Low blood pressure (Systolic pressure: 90 mmHg or less, Diastolic pressure: 50 mmHg or less)
- High blood pressure (Systolic pressure: 140 mmHg or higher, Diastolic pressure: 90 mmHg or less)
- Who is determined ineligible for study participation by investigators for any reason including clinical lab test and ECG results.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01264224
Contacts
| Contact: Namyi Gu, M.D. | +82-2-2072-4083 | nami20@snu.ac.kr |
| Contact: Kyung-Sang Yu, M.D., Ph.D. | +82-2-2072-1930 | ksyu@snu.ac.kr |
Locations
| Korea, Republic of | |
| Seoul National University Hospital Clinical Trials Center | Recruiting |
| Seoul, Korea, Republic of, 110-744 | |
Sponsors and Collaborators
Amorepacific Corporation
Ministry of Knowledge Economy
Investigators
| Principal Investigator: | Kyung-Sang Yu, M.D., Ph.D. | Seoul National University Hospital, Clinical Trials Center/Clinical Research Institute |
More Information
No publications provided
| Responsible Party: | Amorepacific Corporation |
| ClinicalTrials.gov Identifier: | NCT01264224 History of Changes |
| Other Study ID Numbers: | AP-TRPV1-PI-01 |
| Study First Received: | December 20, 2010 |
| Last Updated: | December 28, 2010 |
| Health Authority: | Republic of Korea: Korea Food and Drug Administration |
ClinicalTrials.gov processed this record on May 19, 2013